Billiontoone, Inc. (NASDAQ:BLLN) Receives $126.00 Consensus PT from Analysts

Billiontoone, Inc. (NASDAQ:BLLNGet Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $126.00.

Several analysts have weighed in on BLLN shares. BTIG Research dropped their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Guggenheim assumed coverage on shares of Billiontoone in a research report on Monday, June 29th. They set a “buy” rating and a $125.00 target price on the stock. JPMorgan Chase & Co. raised their target price on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Finally, Weiss Ratings upgraded shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd.

View Our Latest Analysis on Billiontoone

Insider Buying and Selling

In other Billiontoone news, insider Nancy Joann Johnson sold 10,582 shares of Billiontoone stock in a transaction on Tuesday, June 9th. The stock was sold at an average price of $100.47, for a total value of $1,063,173.54. Following the completion of the transaction, the insider directly owned 21,900 shares of the company’s stock, valued at $2,200,293. The trade was a 32.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shan Riku Sakakibara sold 8,000 shares of the company’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $110.00, for a total value of $880,000.00. Following the sale, the insider owned 208,000 shares of the company’s stock, valued at approximately $22,880,000. The trade was a 3.70% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 153,049 shares of company stock worth $16,768,021 in the last quarter.

Institutional Investors Weigh In On Billiontoone

Large investors have recently bought and sold shares of the company. Rossby Financial LCC bought a new stake in shares of Billiontoone during the 4th quarter worth approximately $25,000. Wells Fargo & Company MN acquired a new stake in shares of Billiontoone in the 4th quarter valued at $76,000. Smartleaf Asset Management LLC bought a new position in shares of Billiontoone in the 4th quarter valued at $80,000. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Billiontoone during the 4th quarter worth $82,000. Finally, Renaissance Capital LLC acquired a new position in shares of Billiontoone during the 4th quarter worth $201,000.

Billiontoone Stock Performance

Shares of NASDAQ BLLN opened at $130.31 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. The firm has a market cap of $5.99 billion and a price-to-earnings ratio of 236.93. The stock’s fifty day moving average price is $104.78 and its two-hundred day moving average price is $90.22. Billiontoone has a one year low of $61.96 and a one year high of $138.70.

Billiontoone (NASDAQ:BLLNGet Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The firm had revenue of $108.39 million for the quarter, compared to analyst estimates of $95.81 million. The firm’s quarterly revenue was up 83.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.39) EPS. On average, equities analysts forecast that Billiontoone will post 0.93 EPS for the current year.

About Billiontoone

(Get Free Report)

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

Featured Articles

Analyst Recommendations for Billiontoone (NASDAQ:BLLN)

Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.